BPTF inhibition antagonizes colorectal cancer progression by transcriptionally inactivating Cdc25A

Ping Guo1, Shijia Zu2, Shilong Han1

  • 1Institute of Cancer Stem Cells, Dalian Medical University, Dalian, 116044, China.

Redox Biology
|August 6, 2022
PubMed

Insights

Bromodomain PHD Finger Transcription Factor (BPTF) drives colorectal cancer (CRC) growth by activating Cdc25A, regulated by c-Myc. Inhibiting BPTF shows promise for CRC treatment and prognosis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Bromodomain PHD Finger Transcription Factor (BPTF) is implicated in various cancers.
  • The specific role and mechanisms of BPTF in colorectal cancer (CRC) remain largely undefined.
  • Understanding BPTF's function is crucial for developing novel CRC therapeutic strategies.

Purpose of the Study:

  • To elucidate the function and molecular mechanisms of BPTF in colorectal cancer (CRC) progression.
  • To investigate the regulatory relationship between BPTF, c-Myc, and Cdc25A in CRC.
  • To evaluate the therapeutic potential of targeting BPTF in CRC treatment.

Main Methods:

  • Utilized BPTF-specific siRNAs, shRNAs, and inhibitors to assess proliferation and metastasis.
  • Employed RNA-sequencing, DNA-pulldown, ChIP, and luciferase reporter assays to determine molecular interactions.
  • Validated findings in vitro, in mouse xenograft models, and in AOM/DSS-induced CRC models.

Main Results:

  • BPTF is highly expressed in CRC and promotes proliferation and metastasis by transcriptionally activating Cdc25A.
  • BPTF expression is regulated by c-Myc, forming a c-Myc/BPTF/Cdc25A signaling axis.
  • BPTF inhibition sensitizes CRC cells to chemotherapy (5-FU, Oxaliplatin) and delays tumor growth in vivo.
  • Simultaneous high expression of BPTF, c-Myc, and Cdc25A correlates with poor prognosis in CRC patients.

Conclusions:

  • The c-Myc/BPTF/Cdc25A axis drives CRC progression and is a potential therapeutic target.
  • Targeting BPTF, alone or in combination with chemotherapy, offers a promising strategy for CRC treatment.
  • The c-Myc/BPTF/Cdc25A signaling pathway serves as a valuable biomarker for CRC diagnosis and prognosis.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K